CN104470537B - 表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途 - Google Patents

表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途 Download PDF

Info

Publication number
CN104470537B
CN104470537B CN201380038155.8A CN201380038155A CN104470537B CN 104470537 B CN104470537 B CN 104470537B CN 201380038155 A CN201380038155 A CN 201380038155A CN 104470537 B CN104470537 B CN 104470537B
Authority
CN
China
Prior art keywords
salmonella typhi
plasmid
ty21a
nucleic acid
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380038155.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104470537A (zh
Inventor
D·J·埃科
M·奥索里奥
M·R·富特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN104470537A publication Critical patent/CN104470537A/zh
Application granted granted Critical
Publication of CN104470537B publication Critical patent/CN104470537B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201380038155.8A 2012-05-23 2013-05-22 表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途 Expired - Fee Related CN104470537B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650676P 2012-05-23 2012-05-23
US61/650,676 2012-05-23
PCT/US2013/042240 WO2013177291A1 (en) 2012-05-23 2013-05-22 Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof

Publications (2)

Publication Number Publication Date
CN104470537A CN104470537A (zh) 2015-03-25
CN104470537B true CN104470537B (zh) 2017-04-26

Family

ID=48539444

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380038155.8A Expired - Fee Related CN104470537B (zh) 2012-05-23 2013-05-22 表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途

Country Status (7)

Country Link
US (1) US9409956B2 (enExample)
EP (1) EP2852405B1 (enExample)
JP (1) JP6216371B2 (enExample)
CN (1) CN104470537B (enExample)
IL (1) IL235615A0 (enExample)
IN (1) IN2014DN09618A (enExample)
WO (1) WO2013177291A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806778B2 (en) * 2019-01-30 2020-10-20 Prokarium Limited Modified strain of Salmonella enterica Typhi

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1184505A (zh) * 1995-03-13 1998-06-10 英国国防部 鼠疫疫苗

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856935A (en) 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
GB9326425D0 (en) 1993-12-24 1994-02-23 Secr Defence Vaccine compositions
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DK1108034T3 (da) * 1998-09-04 2008-11-10 Emergent Product Dev Uk Ltd Svækkede salmonella SPI2-mutanter som antigenbærere
GB9921275D0 (en) * 1999-09-10 1999-11-10 Secr Defence Recombinant microorganisms
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
US20070087013A1 (en) * 2003-12-09 2007-04-19 Donata Sizemore Orally-administered live bacterial vaccines for plague
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1184505A (zh) * 1995-03-13 1998-06-10 英国国防部 鼠疫疫苗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Construction and screening of attenuated [Delta]phoP/Q Salmonella typhimurium vectored plague vaccine candidates;SIZEMORE DONATA R ET AL;《HUMAN VACCINES & IMMUNOTHERAPEUTICS》;20120331;第8卷(第3期);371-383 *
Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague;LEARY SOPHIE EC ET AL;《MICROBIAL PATHOGENESIS》;19971231;第23卷(第3期);167-179 *

Also Published As

Publication number Publication date
CN104470537A (zh) 2015-03-25
IN2014DN09618A (enExample) 2015-07-31
US20150152144A1 (en) 2015-06-04
EP2852405A1 (en) 2015-04-01
US9409956B2 (en) 2016-08-09
WO2013177291A8 (en) 2014-12-24
IL235615A0 (en) 2015-01-29
EP2852405B1 (en) 2019-03-13
WO2013177291A1 (en) 2013-11-28
JP2015519061A (ja) 2015-07-09
JP6216371B2 (ja) 2017-10-18

Similar Documents

Publication Publication Date Title
ES2328751T3 (es) Liberacion de polipeptidos biologicamente activos.
Lehours et al. Helicobacter: Inflammation, immunology, and vaccines
Ma et al. Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice
Yunle et al. Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants—A review
Bermúdez-Humarán et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors
US11104916B2 (en) Compositions and methods for alphavirus vaccination
Bermúdez-Humarán Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins
Pasquevich et al. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis
Tarahomjoo Development of vaccine delivery vehicles based on lactic acid bacteria
CN103304670B (zh) 结核分枝杆菌特异性融合蛋白疫苗ab及其制备和应用
US12370248B2 (en) Attenuated salmonella synthesizing antigens for vaccinating against helicobacter pylori
Maurice et al. Oral immunization of Carassius auratus with modified recombinant A-layer proteins entrapped in alginate beads
EP2525817A1 (en) Vaccine vectors and methods of enhancing immune responses
JP2023503057A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
Tadepalli et al. Immunogenicity and protective efficacy of Brucella abortus recombinant protein cocktail (rOmp19+ rP39) against B. abortus 544 and B. melitensis 16M infection in murine model
JP2023503058A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
Wong et al. Recombinant lactococcal-based oral vaccine for protection against Streptococcus agalactiae infections in tilapia (Oreochromis niloticus)
KR101743442B1 (ko) 장독소성 대장균 항원을 발현하는 고스트 살모넬라 변이주를 유효성분으로 포함하는 돼지 부종병의 예방 또는 치료용 백신 조성물
CN104470537B (zh) 表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途
Liu et al. Oral immunization of mice with attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit
CN118873646A (zh) 一种抑制a组链球菌感染的重组蛋白疫苗及其应用
US20240299528A1 (en) A dna plasmid sars-corona virus-2/covid-19 vaccine
US20150238590A1 (en) Use of the salmonella spp type iii secretion proteins as a protective vaccination
CN107158371A (zh) 一种基因工程亚单位二联口服疫苗
Ehteshaminia et al. Next-generation pertussis vaccines with special focus on intranasal vaccination

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170426

Termination date: 20200522